A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

Hypereosinophilic Syndrome Clinical Trial

— NATRON  

Official title:

A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24 Week Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04191304
• Other study ID #: D3254C00001
• Secondary ID: 2019-002039-27
• Status: Recruiting
• Phase: Phase 3
• Start date: July 20, 2020
• Est. completion date: November 20, 2026

Study information

• Verified date: March 2024
• Source: AstraZeneca
• Contact: AstraZeneca Clinical Study Information Center
• Phone: 1-877-240-9479
• Email: information.center[@]astrazeneca.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the 'main study'): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to their prior stable HES background therapy, and an open-label extension (OLE) period, during which all patients will receive benralizumab. Patients will continue to be recruited until approximately 38 patients have had their first HES worsening/flare during the DB treatment period at which point the data cut-off for the primary database lock (DBL) will occur. Treatment allocation will remain blinded until the primary DBL. After the study is unblinded for the primary analysis, patients and investigators will remain blinded to patients' individual treatment allocations until after the final patient completes the DB treatment period. The primary analysis will only include data from the DB treatment period of the study. A follow-up analysis will be performed once all patients have the opportunity to complete the 24-week DB treatment period. A patient must complete the 24-week DB treatment period on investigational product (IP) to be eligible to enter the OLE treatment period. The final DBL will occur after the last patient completes the OLE.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: November 20, 2026
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 130 Years

Eligibility

Inclusion Criteria

1. Provision of the signed and dated written informed consent of the patient or the patient's legally authorised representative, and informed assent from the patient (per local regulations) prior to any mandatory study-specific procedures, sampling, and analyses

2. Males and females 12 years of age and older at the time of signing the ICF

3. Documented diagnosis of HES (history of persistent eosinophilia > 1500 cells/µL without secondary cause on 2 examinations [interval = 1 month; Valent et al 2012] and evidence of end organ manifestations attributable to the eosinophilia)

4. Documented negative testing for the FIP1L1-PDGFRA fusion tyrosine kinase gene translocation

5. Stable HES treatment dose(s) and regimen for = 4 weeks at the time of Visit 1

6. Signs or symptoms of HES worsening/flare and/or laboratory abnormalities indicative of HES worsening/flare (other than isolated eosinophilia) at Visit 1 OR a documented history of 2 or more HES worsening/flares within 12 months prior to Visit 1 requiring an escalation in therapy a. At least one flare within the past 12 months must not be related to a decrease in HES therapy during the 4 weeks prior to the flare

7. AEC = 1000 cells/µL at Visit 1 (assessed by local laboratory)

8. Corticosteroid responsiveness defined as an AEC < 1000 cells/µL after a 2-day course of OCS (prednisone/prednisolone) 1 mg/kg/day at Visit 2 (assessed by local laboratory). Other OCSs in equivalent doses are permitted

9. WOCBP must agree to use a highly effective method of birth control (confirmed by the investigator) from enrolment, throughout the study duration, and within 12 weeks after last dose of IP and have a negative urine dipstick pregnancy test result on Visit 1. Highly effective methods of birth control (those that can achieve a failure rate of

less than 1% per year when used consistently and correctly) include:

1. Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal

2. Progestogen-only hormonal contraception associated with inhibition of ovulation:

oral, injectable, or implantable

3. Intrauterine device

4. Intrauterine hormone-releasing system

5. Bilateral tubal occlusion

6. Sexual abstinence, ie, refraining from heterosexual intercourse (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient)

7. Vasectomised sexual partner (provided that partner is the sole sexual partner of the WOCBP study patient and that the vasectomised partner has received medical assessment of the surgical success) Exclusion Criteria

1. Life-threatening HES and/or HES complication(s) as judged by the investigator:

1. Medical intervention for HES-related life-threatening event(s) within 12 weeks prior to randomization

2. History of thrombotic complications, stroke, or significant cardiac damage related to HES, if the respective events were life threatening and currently represent a risk of life-threatening disease complications. Events that occurred in the past but considered resolved or stable, can be accepted if, as per investigator's judgment, participation in the study will not put the patient at risk

3. Disease severity that in the opinion of the investigator makes the patient inappropriate for inclusion in the study

2. Presence of FIP1L1-PDGFRA fusion tyrosine kinase gene translocation or other known imatinib-sensitive mutation

3. Definitive diagnosis of eosinophilic granulomatosis with polyangiitis

4. Known, preexisting, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities that are not associated with HES and are uncontrolled with standard treatment which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study

5. Hypereosinophilia of unknown significance

6. Cardiovascular: Documented history of any clinically significant cardiac damage, clinically significant echocardiography (if available) or ECG findings within 12 months prior to Visit 1 or clinically significant ECG findings at screening that in the opinion of the investigator may put the patients at risk

7. Known currently active liver disease

1. Chronic stable hepatitis B and C (including positive testing for hepatitis B surface antigen or hepatitis C antibody) or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria. Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice, or cirrhosis

2. ALT or AST level = 3 × ULN during the screening period (AST or ALT > 5 × ULN if documented HES with liver manifestations). Transient increase of AST/ALT level that resolves by the time of randomisation is acceptable if, in the investigator's opinion, the patient does not have an active liver disease and meets other eligibility criteria

8. Current or history of malignancy within 5 years before the screening visit with the

following exceptions:

1. Patients treated for in situ carcinoma of the cervix who have completed curative therapy and are in remission for at least 12 months prior to signing the informed consent and

2. Patients with basal cell or superficial squamous skin cancer

3. Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained

9. Diagnosis of systemic mastocytosis

10. Chronic or ongoing active infections requiring systemic treatment, as well as clinically significant viral, bacterial, or fungal infection within 4 weeks prior to Visit 1

12. A history of known immunodeficiency disorder other than that explained by the use of OCS or other therapy taken for HES. Positive HIV test 14. Evidence of prior benralizumab treatment failure

Related Conditions & MeSH terms

• Hypereosinophilic Syndrome
• Syndrome

Intervention

Biological:
• Benralizumab
Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
• Placebo
Matching placebo solution for injection in an APFS will be administered SC every 4 weeks

Locations

Country	Name	City	State
Austria	Research Site	Innsbruck
Belgium	Research Site	Brussels
Belgium	Research Site	Edegem
Belgium	Research Site	Leuven
Denmark	Research Site	København Ø
France	Research Site	Lille Cedex
France	Research Site	PARIS Cedex 12
France	Research Site	Pessac
France	Research Site	Strasbourg
France	Research Site	Suresnes Cedex
France	Research Site	Toulouse Cedex 9
Germany	Research Site	Hannover
Germany	Research Site	Kirchheim
Germany	Research Site	Mannheim
India	Research Site	Ahmedabad
India	Research Site	Ajmer
India	Research Site	Delhi
India	Research Site	Nagpur
Israel	Research Site	Haifa
Israel	Research Site	Holon
Israel	Research Site	Jerusalem
Israel	Research Site	Kfar Saba
Israel	Research Site	Petah Tiqva
Israel	Research Site	Ramat Gan
Israel	Research Site	Rehovot
Israel	Research Site	Tel-Aviv
Italy	Research Site	Bologna
Italy	Research Site	Milano
Japan	Research Site	Bunkyo-ku
Japan	Research Site	Chiba-shi
Japan	Research Site	Hamamatsu-shi
Japan	Research Site	Ichikawa-shi
Japan	Research Site	Kawasaki-shi
Japan	Research Site	Nishinomiya-shi
Japan	Research Site	Osaka-shi
Japan	Research Site	Sendai-shi
Korea, Republic of	Research Site	Seoul
Netherlands	Research Site	Rotterdam
Poland	Research Site	Checiny
Poland	Research Site	Gdansk
Poland	Research Site	Lódz
Spain	Research Site	Salamanca
Spain	Research Site	Santander
Switzerland	Research Site	Bern
Switzerland	Research Site	Zürich
United Kingdom	Research Site	London
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Atlanta	Georgia
United States	Research Site	Bethesda	Maryland
United States	Research Site	Cleveland	Ohio
United States	Research Site	Columbus	Ohio
United States	Research Site	Durham	North Carolina
United States	Research Site	La Jolla	California
United States	Research Site	Milwaukee	Wisconsin
United States	Research Site	Newport Beach	California
United States	Research Site	Rochester	Minnesota
United States	Research Site	Salt Lake City	Utah
United States	Research Site	Salt Lake City	Utah
United States	Research Site	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Denmark,  France,  Germany,  India,  Israel,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Poland,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to first HES worsening/flare	An HES worsening or flare is defined as HES clinical manifestations or lab abnormalities that result in an increase/burst of OCS =10 mg/day for at least 2 days, OR an increase or addition of new cytotoxic and/or immunosuppressive therapy, OR hospitalisation	Up to 24 weeks
Secondary	Proportion of patients who experience HES worsening/flare		Up to 24 weeks
Secondary	number of HES worsenings/flares	Number of HES worsenings/flares (annualised rate/year) during the DB period	Up to 24 weeks
Secondary	Time to first haematologic relapse	A haematologic relapse is defined as AEC =1000 cells/µL	Up to 24 weeks
Secondary	Change from baseline in fatigue severity	Patient reported measure of fatigue severity (PROMIS fatigue short form 7a)	at week 24
Secondary	Proportion of patients who have haematologic relapse		Up to 24 weeks
Secondary	Proportion of patients who have AEC<500 cells/µL for 24 weeks		Up to 24 weeks
Secondary	Proportion of patients who require an increase in corticosteroid dose	Proportion of patients who require an increase in corticosteroid dose from baseline at any point in the double-blind treatment period	Up to 24 weeks
Secondary	HRQoL	Derived from the SF-36v2 questionnaires which contains 36 questions measuring patients' general functional health and well-being, both physically and mentally	Up to 24 weeks
Secondary	PGIS	The PGIS is a single question evaluating patients' perception of overall symptom severity	Up to 24 weeks
Secondary	PGIC	The PGIC is a single question evaluating whether there has been an improvement or decline in patients' overall health status after start of treatment.	Up to 24 weeks
Secondary	Serum benralizumab concentration as a measure of pharmacokinetics		Up to 24 weeks
Secondary	Anti-drug antibodies (ADA) titers and neutralizing antibodies (nAb) as measure of immunogenicity		Up to 24 weeks
Secondary	Adverse Events (AEs) as an evaluation of safety and tolerability of benralizumab		Up to 24 weeks

External Links

•   The study website.
•   This is a one-page brochure on Natron study.